Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Adoptive T cell cancer therapy

Nature Materials volume 17, pages 475–477 (2018)Cite this article

Subjects

Tumour heterogeneity and off-target toxicity are current challenges of cancer immunotherapy. Karine Dzhandzhugazyan, Per Guldberg and Alexei Kirkin discuss how epigenetic induction of tumour antigens in antigen-presenting cells may form the basis for multi-target therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Current approaches to generating mono- or multi-antigen-directed immune responses for treatment of cancer.

References

  1. Ribas, A. & Wolchok, J. D. Science 359, 1350–1355 (2018).

    Article  Google Scholar 

  2. Rizvi, N. A. et al. Science 348, 124–128 (2015).

    Article  Google Scholar 

  3. Rosenberg, S. A. & Restifo, N. P. Science 348, 62–68 (2015).

    Article  Google Scholar 

  4. June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. Science 359, 1361–1365 (2018).

    Article  Google Scholar 

  5. Morgan, R. A. et al. J. Immunother. 36, 133–151 (2013).

    Article  Google Scholar 

  6. McGranahan, N. et al. Science 351, 1463–1469 (2016).

    Article  Google Scholar 

  7. van der Bruggen, P. et al. Science 254, 1643–1647 (1991).

    Article  Google Scholar 

  8. Robbins, P. F. et al. J. Clin. Oncol. 29, 917–924 (2011).

    Article  Google Scholar 

  9. Kirkin, A. F. et al. Nat. Commun. 9, 785 (2018).

    Article  Google Scholar 

  10. Krishnadas, D. K. et al. Cancer Immunol. Immunother. 64, 1251–1260 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Danish Cancer Society Research Center, Copenhagen, Denmark

    Karine N. Dzhandzhugazyan, Per Guldberg & Alexei F. Kirkin

  2. CytoVac A/S, Hørsholm, Denmark

    Karine N. Dzhandzhugazyan & Alexei F. Kirkin

Authors
  1. Karine N. Dzhandzhugazyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per Guldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexei F. Kirkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexei F. Kirkin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dzhandzhugazyan, K.N., Guldberg, P. & Kirkin, A.F. Adoptive T cell cancer therapy. Nature Mater 17, 475–477 (2018). https://doi.org/10.1038/s41563-018-0094-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41563-018-0094-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing